HENDERSON, Nev. , March 20, 2024 /PRNewswire/ — VolitionRx Restricted (NYSE AMERICAN: VNRX) (“Volition”), a multi-national epigenetics firm, has agreed a provide settlement with Fujifilm Vet Techniques Co. Ltd (“Fujifilm Vet Techniques”), a number one veterinary diagnostic laboratory service, to launch the Nu.Q® Vet Most cancers Check to veterinarians in Japan.
Volition’s provide settlement allows Fujifilm Vet Techniques to promote and carry out most cancers screening providers for canine utilizing the Nu.Q® Vet Most cancers Check all through its community of central reference laboratories in Japan. The Nu.Q® Vet Most cancers Check is an accessible and inexpensive screening instrument for canine to assist in early most cancers detection.
Dr. Tom Butera, Chief Govt Officer, Volition Veterinary Diagnostics Improvement LLC mentioned: “We’re thrilled to be increasing into the Japanese market with Fujifilm Vet Techniques. It’s the nation’s main veterinary diagnostic laboratory service with a community of ten laboratories, supplying veterinary clinics and hospitals nationwide.
“By way of Fujifilm Vet Techniques, Japanese veterinarians could have entry to a cutting-edge check to assist detect most cancers in its early phases, main to higher outcomes and improved affected person care. Our Nu.Q® Vet Most cancers Check is a straightforward, easy-to-use, blood screening check that may be simply built-in into preventive care packages and used alongside different routine bloodwork throughout common wellness visits.”
Dr. Jasmine Kway, Chief Govt Officer of Singapore Volition added:
“Japan is a substantial market alternative for Volition, as we search to broaden our Nu.Q® Vet Most cancers Check providing in Asia. We stay up for working alongside Fujifilm Vet Techniques as they roll out our check countrywide, throughout their diagnostic laboratory community.”
Kiyotaka Fujiwara, Chief Working Officer at Fujifilm Vet Techniques, mentioned: “We’re delighted so as to add the Nu.Q® Vet Most cancers Check to our diagnostic service portfolio and broaden our wellness testing supply to Japanese veterinarians. We’ll notify our clients as quickly because the check is obtainable for buy.”
About Volition
Volition is a multi-national epigenetics firm centered on advancing the science of epigenetics. Volition is devoted to saving lives and enhancing outcomes for folks and animals with life-altering ailments by means of earlier detection, in addition to illness and remedy monitoring.
By way of its subsidiaries, Volition is growing and commercializing easy, straightforward to make use of, cost-effective blood exams to assist diagnose and monitor a spread of ailments, together with some cancers and ailments related to NETosis, comparable to sepsis. Early prognosis and monitoring have the potential not solely to lengthen the lifetime of sufferers, but in addition enhance their high quality of life.
Volition’s analysis and growth actions are centered in Belgium, with an innovation laboratory and workplace within the U.S. and extra workplaces in London and Singapore. Volition’s subsidiary, Belgian Volition SRL is the get together to the availability settlement with Fujifilm Vet Techniques.
The contents discovered at Volition’s web site deal with aren’t integrated by reference into this doc and shouldn’t be thought-about a part of this doc. Such web site deal with is included on this doc as an inactive textual reference solely.
About FUJIFILM VET Techniques
FUJIFILM VET Techniques offers testing providers centered on well being checkups to veterinary medical amenities nationwide. We are able to additionally deal with specialised examinations that can’t be carried out at veterinary hospitals. As well as, we’ve got established contract laboratories at 10 bases in Japan, and we’ve got led the market by offering providers that rapidly report check outcomes by using our testing community and specimen assortment community. Veterinarians at veterinary hospitals and clinics nationwide have praised its promptness and comfort.
Media Enquiries:
Louise Batchelor/Debra Daglish, Volition, [email protected] +44 (0)7557 774620
Protected Harbor Assertion
Statements on this press launch could also be “forward-looking statements” inside the which means of Part 27A of the Securities Act of 1933, as amended, and Part 21E of the Securities Alternate Act of 1934, as amended, that concern issues that contain dangers and uncertainties that might trigger precise outcomes to vary materially from these anticipated or projected within the forward-looking statements. Phrases comparable to “expects,” “anticipates,” “intends,” “plans,” “goals,” “targets,” “believes,” “seeks,” “estimates,” “optimizing,” “potential,” “objective,” “suggests,” “might,” “would,” “ought to,” “could,” “will” and comparable expressions determine forward-looking statements. These forward-looking statements relate to, amongst different subjects, Volition’s estimated market alternative, the effectiveness of Volition’s blood-based diagnostic, prognostic and illness monitoring exams, and Volition’s capability to develop and efficiently commercialize such check platforms for early detection of most cancers and different ailments in addition to serving as a diagnostic, prognostic or illness monitoring instruments for such ailments. Volition’s precise outcomes could differ materially from these indicated in these forward-looking statements on account of quite a few dangers and uncertainties, together with, with out limitation, outcomes of research testing the efficacy of its exams. As an illustration, if Volition fails to develop and commercialize diagnostic, prognostic or illness monitoring merchandise, it might be unable to execute its plan of operations. Different dangers and uncertainties embrace Volition’s failure to acquire mandatory regulatory clearances or approvals to distribute and market future merchandise; a failure by {the marketplace} to simply accept the merchandise in Volition’s growth pipeline or every other diagnostic, prognostic or illness monitoring merchandise Volition would possibly develop; Volition’s failure to safe satisfactory mental property safety; Volition will face fierce competitors and Volition’s meant merchandise could change into out of date as a result of extremely aggressive nature of the diagnostics and illness monitoring market and its fast technological change; downturns in home and overseas economies; and different dangers recognized in Volition’s most up-to-date Annual Report on Type 10-Ok and Quarterly Stories on Type 10-Q, in addition to different paperwork that Volition information with the Securities and Alternate Fee. These statements are based mostly on present expectations, estimates and projections about Volition’s enterprise based mostly, partly, on assumptions made by administration. These statements aren’t ensures of future efficiency and contain dangers, uncertainties and assumptions which can be tough to foretell. Ahead-looking statements are made as of the date of this launch, and, besides as required by regulation, Volition doesn’t undertake an obligation to replace its forward-looking statements to replicate future occasions or circumstances.
Nucleosomics™ and Nu.Q® and their respective logos are emblems and/or service marks of VolitionRx Restricted and its subsidiaries. All different emblems, service marks and commerce names referred to on this press launch are the property of their respective homeowners.
SOURCE VolitionRx Restricted